학술논문
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
Document Type
Article
Author
Source
In: Cost Effectiveness and Resource Allocation . (Cost Effectiveness and Resource Allocation, 15 January 2020, 18(1))
Subject
Language
English
ISSN
14787547